Skip to main content
. Author manuscript; available in PMC: 2011 Aug 1.
Published in final edited form as: J Autoimmun. 2010 Feb 20;35(1):33–44. doi: 10.1016/j.jaut.2010.01.003

Table 2.

Clinical evaluation of the effect of MOG35–55-CD8+ T cells on ongoing EAE (cumulative data from three experiments).

Condition Experiment duration (day) Incidence Mortality Onset (day) Peak score Cumulative score Average clinical score Outcome Grade of remission
OVA-CD8+ 36 12/12 0/0 15.67 2.98 50.37 1.39 2.62 0.37
MOG-CD8+ 36 12/12 0/0 15.67 2.25 * 36.04 * 1.00 * 1.73 * 0.53

MOG-CD8+ clinical data were statistically compared to OVA-CD8+ data.

*

p ≤ 0.05.